anti-ny eso-1 tcr-transduced t cells

Cell therapyexperimental

Clinical trial activity

7 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2015 (NCT02457650)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • anti-ny eso-1 tcr-transduced t cells
  • anti-ny-eso-1 tcr transduced t cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06942143Phase 1May 22, 2025Guangzhou FineImmune Biotechnology Co., LTD., Sun Yat-Sen University
NCT06889766Phase 1Mar 24, 2025University of Lausanne
NCT06083883Phase 1Feb 1, 2024University of Texas at Houston
NCT06066359Phase 1/Phase 2 (Phase 2)Nov 30, 2023University of Texas at Houston
NCT05620693N/ANov 11, 2022Shenzhen University
NCT03029273Phase 1Mar 1, 2017Guangdong Xiangxue Precision Medical Technology Co., Ltd, Guangzhou Medical University, Guangzhou Xiangxue Pharmaceutical Co., Ltd, Xiangxue Life Science Research Center
NCT02457650Phase 1Apr 1, 2015China Medical University, Shenzhen Institute for Innovation and Translational Medicine
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of Texas at HoustonAcademic/Hospital2222023
China Medical UniversityAcademic/Hospital1112015
Guangdong Xiangxue Precision Medical Technology Co., LtdFor profit1012017
Guangzhou FineImmune Biotechnology Co., LTD.Government1112025
Guangzhou Medical UniversityAcademic/Hospital1112017
Guangzhou Xiangxue Pharmaceutical Co., LtdFor profit1012017
Shenzhen Institute for Innovation and Translational MedicineAcademic/Hospital1012015
Shenzhen UniversityAcademic/Hospital1112022
Sun Yat-Sen UniversityAcademic/Hospital1012025
University of LausanneAcademic/Hospital1112025
Xiangxue Life Science Research CenterAcademic/Hospital1012017
11 organizations
Page 1 / 1